Hydroquinidine
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Hydroquinidine is a medication indicated in the maintenance of a normal sinus rhythm, as well as the treatment and prevention of abnormal rhythm.
- Generic Name
- Hydroquinidine
- DrugBank Accession Number
- DB15300
- Background
Hydroquinidine is under investigation in clinical trial NCT00927732 (Hydroquinidine Versus Placebo in Patients With Brugada Syndrome).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 326.44
Monoisotopic: 326.199428085 - Chemical Formula
- C20H26N2O2
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Atrial fibrillation or flutter •••••••••••• ••••• •••••• Prophylaxis of Paroxysmal supraventricular tachycardia •••••••••••• ••••• •••••• Maintenance of Sinus rhythm •••••••••••• ••••• •••••• Maintenance of Sinus rhythm •••••••••••• ••••• •••••• Treatment of Supraventricular arrhythmias •••••••••••• ••••• •••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol Acebutolol may increase the arrhythmogenic activities of Hydroquinidine. Acetyldigitoxin Acetyldigitoxin may increase the arrhythmogenic activities of Hydroquinidine. Adenosine Adenosine may increase the arrhythmogenic activities of Hydroquinidine. Ajmaline Ajmaline may increase the arrhythmogenic activities of Hydroquinidine. Amiodarone Amiodarone may increase the QTc-prolonging activities of Hydroquinidine. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- C01BA13 — Hydroquinidine
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8P68XPY4HG
- CAS number
- 1435-55-8
- InChI Key
- LJOQGZACKSYWCH-LHHVKLHASA-N
- InChI
- InChI=1S/C20H26N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h4-6,8,11,13-14,19-20,23H,3,7,9-10,12H2,1-2H3/t13-,14-,19+,20-/m0/s1
- IUPAC Name
- (S)-[(1S,2R,4S,5R)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol
- SMILES
- [H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2CC)[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12
References
- General References
- AIFA Product Information: IDROCHINIDINA LIRCA (hydroquinidine hydrochloride) oral tablet [Link]
- External Links
- ChemSpider
- 82624
- 27220
- ChEMBL
- CHEMBL531472
- ZINC
- ZINC000003977899
- Wikipedia
- Dihydroquinidine
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Terminated Treatment Brugada Syndrome (BrS) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Cream Tablet Oral 150 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.312 mg/mL ALOGPS logP 3.36 ALOGPS logP 2.82 Chemaxon logS -3 ALOGPS pKa (Strongest Acidic) 13.89 Chemaxon pKa (Strongest Basic) 9.18 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 45.59 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 94.65 m3·mol-1 Chemaxon Polarizability 36.67 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-004i-0009000000-5fd9192ebf49428a6342 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004l-0498000000-0c955987e5cc615a03d5 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-004i-0009000000-154760bc96c0695902cf Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0a70-0938000000-7dc41a151824cf123542 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0230-0921000000-da0b4f0d362a8e5e64c2 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0abc-0910000000-a00a1d8b25080afa5400 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 189.9813924 predictedDarkChem Lite v0.1.0 [M-H]- 190.5648924 predictedDarkChem Lite v0.1.0 [M+H]+ 190.2063924 predictedDarkChem Lite v0.1.0 [M+H]+ 191.1180924 predictedDarkChem Lite v0.1.0 [M+Na]+ 190.4913924 predictedDarkChem Lite v0.1.0 [M+Na]+ 190.6917924 predictedDarkChem Lite v0.1.0
Drug created at May 20, 2019 15:09 / Updated at September 25, 2021 23:52